We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Microsoft, Alphabet, Eli Lilly, Visa and Morgan Stanley
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , Alphabet Inc. (GOOGL - Free Report) , Eli Lilly and Co. (LLY - Free Report) , Visa Inc. (V - Free Report) and Morgan Stanley (MS - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Microsoft, Alphabet and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., Alphabet Inc. and Eli Lilly and Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Microsoft shares have held up relatively better compared to the software space (down -23.2% over the past year against the Zacks Computer - Software industry’s decline of -31.6%) and modestly worse than the broader market's -20.4% decline.
Beyond some softening demand for the company's services over the near to medium-term as a result of rising interest rates in response to inflationary pressures, Microsoft's business is as rock solid today as it was last year.
The company’s increasing spend on Azure enhancements amid stiff competition in the cloud space from Amazon is likely to dent margins. However, Microsoft’s performance is benefiting from strength in its Azure cloud platform amid accelerated global digital transformation.
Teams’ user growth is gaining from continuation of remote work and mainstream adoption of hybrid/flexible work models. Recovery in the advertising and job market boosted LinkedIn and Search revenues. Solid uptake of new Xbox consoles is aiding the gaming segment performance.
The company is witnessing growth in the user base of its different applications including Microsoft 365 suite, Dynamics and Power Platform. Microsoft expects Surface revenues to grow in the mid-teens range, driven by strong demand for premium devices.
Alphabet shares have lost -32.3% of their value in the year-to-date period vs. -35.7% decline for the Zacks Internet Services industry and -25.5% decline for the S&P 500 index. A relatively subdued ad spending outlook given the macroeconomic headwinds is the biggest worry in the Alphabet story. But this is no more than a short to medium-term issue, as the long-term outlook for all of Alphabet's businesses, including digital advertising, remains favorable.
The Zacks analysts believe for 2022, Google Cloud revenue to grow 24.7% from 2021. Further, major updates in its search segment are enhancing the search results. Moreover, Google’s mobile search is gaining solid momentum. For 2022, we anticipate Google Search revenue to be up 11% from the last year.
Also, strong focus on innovation of AI techniques and the home automation space should continue aiding Alphabet’s business growth in the days ahead. Its deepening focus on the wearables category remains a tailwind. Also, Alphabet’s expanding presence in the autonomous driving space is contributing well. Considering the aforesaid factors, we expect 2022 total revenue to grow 10.3% from 2021.
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+37.2% vs. +6.5%). The company’s revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. It is regularly adding promising new pipeline assets through business development deals.
Lilly expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease. Both drugs have multibillion dollar sales potential.
However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drugs, Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds. Estimates have gone down slightly ahead of Q3 results. Lilly has a negative record of earnings surprises in the recent quarters.
Other noteworthy reports we are featuring today include Visa Inc. and Morgan Stanley.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Microsoft, Alphabet, Eli Lilly, Visa and Morgan Stanley
For Immediate Release
Chicago, IL – October 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , Alphabet Inc. (GOOGL - Free Report) , Eli Lilly and Co. (LLY - Free Report) , Visa Inc. (V - Free Report) and Morgan Stanley (MS - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Microsoft, Alphabet and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., Alphabet Inc. and Eli Lilly and Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Microsoft shares have held up relatively better compared to the software space (down -23.2% over the past year against the Zacks Computer - Software industry’s decline of -31.6%) and modestly worse than the broader market's -20.4% decline.
Beyond some softening demand for the company's services over the near to medium-term as a result of rising interest rates in response to inflationary pressures, Microsoft's business is as rock solid today as it was last year.
The company’s increasing spend on Azure enhancements amid stiff competition in the cloud space from Amazon is likely to dent margins. However, Microsoft’s performance is benefiting from strength in its Azure cloud platform amid accelerated global digital transformation.
Teams’ user growth is gaining from continuation of remote work and mainstream adoption of hybrid/flexible work models. Recovery in the advertising and job market boosted LinkedIn and Search revenues. Solid uptake of new Xbox consoles is aiding the gaming segment performance.
The company is witnessing growth in the user base of its different applications including Microsoft 365 suite, Dynamics and Power Platform. Microsoft expects Surface revenues to grow in the mid-teens range, driven by strong demand for premium devices.
(You can read the full research report on Microsoft here >>>)
Alphabet shares have lost -32.3% of their value in the year-to-date period vs. -35.7% decline for the Zacks Internet Services industry and -25.5% decline for the S&P 500 index. A relatively subdued ad spending outlook given the macroeconomic headwinds is the biggest worry in the Alphabet story. But this is no more than a short to medium-term issue, as the long-term outlook for all of Alphabet's businesses, including digital advertising, remains favorable.
The Zacks analysts believe for 2022, Google Cloud revenue to grow 24.7% from 2021. Further, major updates in its search segment are enhancing the search results. Moreover, Google’s mobile search is gaining solid momentum. For 2022, we anticipate Google Search revenue to be up 11% from the last year.
Also, strong focus on innovation of AI techniques and the home automation space should continue aiding Alphabet’s business growth in the days ahead. Its deepening focus on the wearables category remains a tailwind. Also, Alphabet’s expanding presence in the autonomous driving space is contributing well. Considering the aforesaid factors, we expect 2022 total revenue to grow 10.3% from 2021.
(You can read the full research report on Alphabet here >>>)
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+37.2% vs. +6.5%). The company’s revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. It is regularly adding promising new pipeline assets through business development deals.
Lilly expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease. Both drugs have multibillion dollar sales potential.
However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drugs, Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds. Estimates have gone down slightly ahead of Q3 results. Lilly has a negative record of earnings surprises in the recent quarters.
(You can read the full research report on Eli Lilly here >>>)
Other noteworthy reports we are featuring today include Visa Inc. and Morgan Stanley.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.